MYEOV and pancreatic neoplasm: Our data suggest that the suppression of MYEOV expression is a new factor leading to a poor prognosis in pancreatic cancer patients through activation of c-Myc and mTORC1 and metabolic remapping, such as enhancement of the one-carbon metabolic pathway.